LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of “Hold” by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have earned an average rating of “Hold” from the nine analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $110.60.

LMAT has been the topic of several analyst reports. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, August 14th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Finally, Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently made changes to their positions in LMAT. Royal Bank of Canada boosted its holdings in shares of LeMaitre Vascular by 1.5% in the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after acquiring an additional 1,735 shares in the last quarter. AQR Capital Management LLC raised its holdings in LeMaitre Vascular by 36.4% during the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after purchasing an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in LeMaitre Vascular by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock worth $1,013,000 after purchasing an additional 539 shares during the period. Millennium Management LLC lifted its position in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in LeMaitre Vascular by 27.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $78.97 on Wednesday. LeMaitre Vascular has a 52 week low of $78.29 and a 52 week high of $118.01. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of 27.71, a price-to-earnings-growth ratio of 2.31 and a beta of 0.53. The company has a 50-day moving average price of $93.85 and a two-hundred day moving average price of $99.56.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The firm had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. LeMaitre Vascular’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.60 EPS. Analysts forecast that LeMaitre Vascular will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.3%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 35.09%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.